Alzheimer's Disease (AD)

Alzheimer’s disease is the most common form of dementia, which progressively worsens with age.  Though individuals can live with the disease for up to 20 years, it is still considered the 6th leading cause of death in the US. Presently, 5.4 million Americans have Alzheimer’s disease and that number may top 13.2 million by 2050. This devastating disorder may begin as a mild form causing new memory loss, but progresses to the point that the patient needs help with all daily functions. Though caregivers provide 17 billion unpaid hours, eventually, in the later stages, patients are placed in facilities that can provide the 24 hour a day assistance. This cost to society is in the range of 183 billion dollars annually. Unfortunately, there are no cures for the disease and the present AD therapies moderately reduce the symptoms of the disease, without reversing the deficit or improving cognition. 

Neuronascent has discovered and is developing a new class of neuro-restorative therapeutics that is aimed at reversing  the cognitive deficit in AD patients by stimulating and protecting new neuron growth. Neuronascent's patented, orally-active neurogenic lead therapeutic aims to replace lost and damaged neurons in key degenerating regions of the adult human brain. Laboratory tests indicate that this lead therapeutic candidate increases the number of brain cells, leading to memory improvement.  In mice, these are truly brain-changing events that should provide more than just symptomatic relief. Our AD therapeutic candidate, NNI-362 is in the preclinical phase of development, where we are now initiating IND-enabling studies.

For more information on Alzheimer's disease, please visit the Alzheimer's Association website at www.alz.org.”